Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Apr 12, 2024

BUY
$5.55 - $19.62 $1,110 - $3,924
200 New
200 $3,000
Q3 2021

Oct 26, 2021

SELL
$30.95 - $120.97 $83,565 - $326,619
-2,700 Closed
0 $0
Q2 2021

Jul 14, 2021

BUY
$21.55 - $96.1 $58,185 - $259,469
2,700 New
2,700 $231,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $18.9M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Game Plan Financial Advisors, LLC Portfolio

Follow Game Plan Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Game Plan Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Game Plan Financial Advisors, LLC with notifications on news.